As of 2026-04-07, the EV/EBITDA ratio of Maravai LifeSciences Holdings Inc (MRVI) is -16.18. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. MRVI's latest enterprise value is 864.34 mil USD. MRVI's TTM EBITDA according to its financial statements is -53.42 mil USD. Dividing these 2 quantities gives us the above MRVI EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 12.5x - 13.5x | 12.8x |
| Forward P/E multiples | 17.0x - 22.2x | 20.0x |
| Fair Price | (3.95) - (3.23) | (3.83) |
| Upside | -234.0% - -209.4% | -229.7% |
| Date | EV/EBITDA |
| 2026-04-06 | -16.18 |
| 2026-04-02 | -16.18 |
| 2026-04-01 | -15.79 |
| 2026-03-31 | -15.60 |
| 2026-03-30 | -15.84 |
| 2026-03-27 | -15.75 |
| 2026-03-26 | -16.85 |
| 2026-03-25 | -16.95 |
| 2026-03-24 | -16.81 |
| 2026-03-23 | -16.76 |
| 2026-03-20 | -16.32 |
| 2026-03-19 | -16.56 |
| 2026-03-18 | -16.66 |
| 2026-03-17 | -17.00 |
| 2026-03-16 | -17.14 |
| 2026-03-13 | -16.81 |
| 2026-03-12 | -17.82 |
| 2026-03-11 | -19.07 |
| 2026-03-10 | -18.83 |
| 2026-03-09 | -19.45 |
| 2026-03-06 | -19.07 |
| 2026-03-05 | -19.69 |
| 2026-03-04 | -20.37 |
| 2026-03-03 | -19.74 |
| 2026-03-02 | -19.36 |
| 2026-02-27 | -19.11 |
| 2026-02-26 | -19.11 |
| 2026-02-25 | -17.67 |
| 2026-02-24 | -17.00 |
| 2026-02-23 | -16.71 |
| 2026-02-20 | -16.90 |
| 2026-02-19 | -16.81 |
| 2026-02-18 | -16.32 |
| 2026-02-17 | -16.08 |
| 2026-02-13 | -16.23 |
| 2026-02-12 | -16.52 |
| 2026-02-11 | -17.00 |
| 2026-02-10 | -17.00 |
| 2026-02-09 | -16.95 |
| 2026-02-06 | -17.09 |
| 2026-02-05 | -16.85 |
| 2026-02-04 | -17.72 |
| 2026-02-03 | -17.67 |
| 2026-02-02 | -18.20 |
| 2026-01-30 | -18.15 |
| 2026-01-29 | -18.49 |
| 2026-01-28 | -18.44 |
| 2026-01-27 | -20.27 |
| 2026-01-26 | -19.79 |
| 2026-01-23 | -19.84 |